About: Bio-Israel

Medicortex has launched a crowdfunding campaign in order to generate support for developing a diagnostic kit for brain injury detection. The target is 200,000 Euro with a maximum of 560,000 Euro offering equity of between 4.76 and 12.28 percent. The price per share is 4 Euro with a minimum investment...

The U.S. Food and Drug Administration approved Mobile ODT’s EVA (Enhanced Visual Assessment) System for marketing and sale in the United States. The tragedy of cervical cancer – strongly addressed in major urban areas – still plagues much of America, where it is increasingly difficult for a woman to get...

Compugen Ltd. (NASDAQ: CGEN) announced development of CGEN-15137, its cancer immunotherapy program for TIGIT. TIGIT is an immune checkpoint in the B7/CD28 family which has recently gained broad industry interest in the field of immuno-oncology. At the recent Annual Meeting of the Society for Immunotherapy of Cancer, the company disclosed...

Cancer treatment company BioSight, which recently received a $13 million investment from Mori Arkin and US investment fund Primera Capital, reports positive interim results of an initial efficacy trial for its Leukemia treatment product. The company’s product, Astarabine, had been tested on 15 Acute Myeloid Leukemia (AML) and Acute Lymphoblastic...

Israeli high-tech companies raised a total of $1.19 billion in the third quarter of 2016, the second highest quarterly amount in 10 years. The amount was significantly affected by the exceptional Ormat PIPE deal of $204 million, which captured 17 percent of total capital raised. Excluding the Ormat transaction, the...